The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 701–800 of 1,027
Maji, D., Shaikh, S. S., Solanki, D., & Gaurav, K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113754 · Cited by 83
Gharacholou, S. M., Lópes, R. D., Alexander, K. P., Mehta, R. H., Stebbins, A., Pieper, K. S., James, S. K., Armstrong, P. W., & Granger, C. B. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.36 · Cited by 83
Statins: Beneficial or Adverse for Glucose Metabolism
Sasaki, J. D., Iwashita, M., & Kono, S. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.123 · Cited by 83
Foley, T. R., Singh, G. D., Kokkinidis, D. G., Choy, H.-H., Pham, T. H., Amsterdam, E. A., Rutledge, J. C., Waldo, S. W., Armstrong, E. J., & Laird, J. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005699 · Cited by 83
Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.053 · Cited by 82
Self-citationNanna, M. G., Navar, A. M., Wang, T. Y., Mi, X., Virani, S. S., Louie, M. J., Lee, L. V., Goldberg, A. C., Roger, V. L., Robinson, J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008546 · Cited by 82
Sezaki, H., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Kobayashi, M., Suzuki, Y., Arase, Y., Ikeda, K., Miyakawa, Y., et al. (2009) · Intervirology · doi:10.1159/000213504 · Cited by 82
National Lipid Association Annual Summary of Clinical Lipidology 2015
Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 82
Oesterle, A., & Liao, J. K. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180817155058 · Cited by 82
de Haan, W., van der Hoogt, C. C., Westerterp, M., Hoekstra, M., Dallinga‐Thie, G. M., Princen, H. M. G., Romijn, J. A., Jukema, J. W., Havekes, L. M., & Rensen, P. C. N. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.001 · Cited by 82
FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice
Yakala, G. K., Cabrera-Fuentes, H. A., Crespo-Avilan, G. E., Rattanasopa, C., Burlacu, A., George, B. L., Anand, K., Mayan, D. C., Corlianò, M., Hernández‐Reséndiz, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311903 · Cited by 82
Tardif, J., Grégoire, J. C., L’Allier, P. L., Ibrahim, R., Anderson, T. J., Reeves, F., Title, L. M., Schampaert, É., Lemay, M., Lespérance, J., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.039 · Cited by 82
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 81
Plaque progression and regression in atherothrombosis
Ibáñez, B., Vilahur, G., & Badimón, J. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02483.x · Cited by 81
Poli, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00002 · Cited by 81
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Cavender, M. A., Scirica, B. M., Bonaca, M. P., Angiolillo, D. J., Dalby, A. J., Dellborg, M., Morais, J., Murphy, S. A., Ophuis, T. O., Tendera, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013774 · Cited by 80
Self-citationRosuvastatin safety: lessons from the FDA review and post-approval surveillance
Davidson, M. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.547 · Cited by 80
Ezetimibe: an update on its clinical usefulness in specific patient groups
Hammersley, D. J., & Signy, M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316672544 · Cited by 80
Foody, J. M., Rathore, S. S., Galusha, D. H., Masoudi, F. A., Havranek, E. P., Radford, M. J., & Krumholz, H. M. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00635.x · Cited by 80
Cardiovascular disease in HIV-positive patients
Kamin, D., & Grinspoon, S. K. (2005) · AIDS · doi:10.1097/01.aids.0000166087.08822.bc · Cited by 80
Danik, J. S., Chasman, D. I., Cannon, C. P., Miller, D. T., Zee, R. Y. L., Kozłowski, P., Kwiatkowski, D. J., & Ridker, P. M. (2006) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2006.00272.x · Cited by 80
Self-citationForrester, J. S., Makkar, R., & Shah, P. K. (2005) · Circulation · doi:10.1161/01.cir.0000160860.36911.bd · Cited by 80
Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?
Ray, K. K., & Cannon, C. P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.027 · Cited by 80
Self-citationMental Illness and the Criminal Justice System
Hiday, V. A., & Burns, P. J. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511984945.029 · Cited by 79
Statin myopathy: a review of recent progress
Mammen, A. L., & Amato, A. A. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833f0fc7 · Cited by 79
Khakoo, A. Y., & Yeh, E. T. H. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1225 · Cited by 79
Gazi, I. F., Daskalopoulou, S. S., Nair, D. R., & Mikhailidis, D. P. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226267 · Cited by 79
High-Density Lipoprotein Metabolism: Potential Therapeutic Targets
Davidson, M. H., & Toth, P. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.011 · Cited by 79
de Lemos, J. A., Blazing, M. A., & Wiviott, S. D. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.10.005 · Cited by 79
Management of Dyslipidemia in the Metabolic Syndrome
Ascaso, J. F., Santos, P. G., Mijares, A. H., Mangas, A., Masana, L., Millán, J., Pallardo, L. F., Pedro‐Botet, J., Jiménez, F. P., Pintó, X., et al. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707010-00004 · Cited by 79
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 78
GPR109A and Vascular Inflammation
Chai, J. T., Digby, J. E., & Choudhury, R. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0325-9 · Cited by 78
Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?
Holbrook, A. M., Wright, M. S. W., Sung, M., Ribic, C. M., & Baker, S. K. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.024 · Cited by 78
The Year in Interventional Cardiology
Dixon, S. R., Grines, C. L., & O’Neill, W. W. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.021 · Cited by 78
Dyslipidemia in type 2 diabetes mellitus
Gadi, R., & Samaha, F. F. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0036-0 · Cited by 78
Part 5: Acute coronary syndromes
Nikolaou, N. I., Welsford, M., Beygui, F., Bossaert, L. L., Ghaemmaghami, C. A., Nonogi, H., O’Connor, R. E., Pichel, D. R., Scott, T., Walters, D., et al. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.07.043 · Cited by 78
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Zhao, S., Yu, B., Peng, D., & Huo, Y. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.003 · Cited by 77
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
Holdaas, H., Fellström, B., Jardine, A. G., Nyberg, G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H., Cole, E., Maes, B., Ambühl, P. M., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh735 · Cited by 77
Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety
Kulik, A., & Ruel, M. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903188413 · Cited by 76
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 76
Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
Etemad, L. R., & McCollam, P. L. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.4.300 · Cited by 76
Ademi, Z., Watts, G. F., Juniper, A., & Liew, D. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.280 · Cited by 76
Modern Management of Acute Myocardial Infarction
Yang, E. H., Brilakis, E. S., Reeder, G. S., & Gersh, B. J. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.08.004 · Cited by 76
Psychological Approaches to Mental Illness
Peterson, C. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511984945.008 · Cited by 77
Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke
Kim, J., Lee, H. S., Nam, C. M., & Heo, J. H. (2017) · Stroke · doi:10.1161/strokeaha.117.018140 · Cited by 76
‘Hypertension’ and ‘microalbuminuria’: The bell tolls for thee
Forman, J. P., & Brenner, B. M. (2005) · Kidney International · doi:10.1038/sj.ki.5000056 · Cited by 76
Chan, P. S., Nallamothu, B. K., Gurm, H. S., Hayward, R. A., & Vijan, S. S. (2007) · Circulation · doi:10.1161/circulationaha.106.667683 · Cited by 76
Demina, E. P., Smutova, V., Pan, X., Fougerat, A., Guo, T., Zou, C., Chakraberty, R., Snarr, B. D., Shiao, T. C., Roy, R., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018756 · Cited by 75
Do we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros, V. G., Kakafika, A. I., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.026 · Cited by 75
Enas, E. A., Chacko, V., Senthilkumar, A., Puthumana, N., & Mohan, V. (2006) · Disease-a-Month · doi:10.1016/j.disamonth.2006.01.002 · Cited by 75
Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes
Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S. A., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.087957 · Cited by 75
Self-citationMärz, W., Seelhorst, U., Wellnitz, B., Tiran, B., Obermayer-Pietsch, B. M., Renner, W., Boehm, B. O., Ritz, E., & Hoffmann, M. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0071 · Cited by 75
Majithia, A., Bhatt, D. L., Friedman, A. N., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055560 · Cited by 74
Rosada, A., Kassner, U., Weidemann, F., König, M., Buchmann, N., Steinhagen‐Thiessen, E., & Spira, D. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01277-9 · Cited by 74
Antonopoulos, A. S., Margaritis, M., Shirodaria, C. C., & Antoniades, C. A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-05-0337 · Cited by 74
Woodard, J., Sassano, A., Hay, N., & Platanias, L. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5232 · Cited by 74
Chhatriwalla, A. K., Nicholls, S. J., Wang, T. H., Wolski, K., Sipahi, İ., Crowe, T., Schoenhagen, P., Kapadia, S. R., Tuzcu, E. M., & Nissen, S. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.065 · Cited by 74
Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm
Ishii, M., Kaikita, K., Sato, K., Yamanaga, K., Miyazaki, T., Akasaka, T., Tabata, N., Arima, Y., Sueta, D., Sakamoto, K., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003426 · Cited by 74
Leibowitz, M., Karpati, T., Cohen-Stavi, C. J., Feldman, B., Hoshen, M., Bitterman, H., Suissa, S., & Balicer, R. D. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2751 · Cited by 74
Kandzari, D. E., Roe, M. T., Chen, A. Y., Lytle, B. L., Pollack, C. V., Harrington, R. A., Ohman, E. M., Gibler, W. B., & Peterson, E. D. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.014 · Cited by 74
Mui, K.-W., Sleeswijk, M. E., van den Hout, H., van Baal, J. G., Navis, G. J., & Woittiez, A.-J. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080827 · Cited by 74
Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance
Biasucci, L. M., Biasillo, G., & Stefanelli, A. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.277 · Cited by 73
Berberine – a novel approach to cholesterol lowering
Doggrell, S. A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.5.683 · Cited by 73
Saito, Y. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70886-8 · Cited by 73
Ultrasound imaging techniques for the evaluation of cardiovascular therapies
Kastelein, J. J. P., & de Groot, E. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn070 · Cited by 73
Morrow, D. A., Scirica, B. M., Karwatowska‐Prokopczuk, E., Skene, A. M., McCabe, C. H., & Braunwald, E. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.01.004 · Cited by 73
Self-citationYu, C., Zhang, Q., Lam, L., Lin, H., Kong, S. L., Chan, W., Fung, J. W.-H., Cheng, K. K. K., Chan, I. H. S., Lee, S. W.-L., et al. (2007) · Heart · doi:10.1136/hrt.2006.102848 · Cited by 73
Benefit of Intensive Statin Therapy in Women
Truong, Q. A., Murphy, S. A., McCabe, C. H., Armani, A. M., & Cannon, C. P. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957720 · Cited by 73
Self-citationYajima, S., Hara, K., Sanders, J. M., Yin, F., Ohsawa, K., Wiesner, J., Jomaa, H., & Oldfield, E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja040126m · Cited by 73
Perspectives on Dyslipidemia and Coronary Heart Disease in Women
Bittner, V. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.089 · Cited by 73
LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker
Aggarwal, D. J., Kathariya, G., & Verma, P. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.07.013 · Cited by 72
The AIM-HIGH Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.017 · Cited by 72
Pitt, B., Loscalzo, J., Monyak, J. T., Miller, E., & Raichlen, J. S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.12.015 · Cited by 72
Plaque Stabilization: Can We Turn Theory into Evidence?
Libby, P., & Sasiela, W. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.017 · Cited by 72
C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?
Lavie, C. J., Milani, R. V., Verma, A., & O’Keefe, J. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181c61b66 · Cited by 72
Kotseva, K., Stagmo, M., Bacquer, D. D., Backer, G. D., & Wood, D. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.004 · Cited by 72
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 72
Self-citationKapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.39 · Cited by 72
Effect of statin therapy on the progression of coronary atherosclerosis
Tian, J., Gu, X., Sun, Y., Ban, X., Xiao, Y., Hu, S., & Yu, B. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-70 · Cited by 72
Informational lobbying under the shadow of political pressure
Dahm, M., & Porteiro, N. (2007) · Social Choice and Welfare · doi:10.1007/s00355-007-0264-x · Cited by 72
Schwartz, G. G., OLSSON, A. G., Szarek, M. J., & Sasiela, W. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2508 · Cited by 72
Statin Use in Outpatients With Obstructive Coronary Artery Disease
Arnold, S. V., Spertus, J. A., Tang, F., Krumholz, H. M., Borden, W. B., Farmer, S. A., Ting, H. H., & Chan, P. S. (2011) · Circulation · doi:10.1161/circulationaha.111.038265 · Cited by 72
Zhong, Z., Hou, J., Zhang, Q.-F., Zhong, W. H., Li, B., Li, C., Liu, Z., Yang, M. H., & Zhao, P. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-0979-6 · Cited by 72
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 72
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L. D., Doody, R. S., Waters, D. D., Hey‐Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.02.001 · Cited by 72
McKenney, J. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.007 · Cited by 72
American Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
Atherosclerosis: from biology to pharmacological treatment
Riccioni, G., & Sblendorio, V. T. (2012) · 老年心脏病学杂志：英文版 · doi:10.3724/sp.j.1263.2012.02132 · Cited by 71
The correlation between serum lipid profile with carotid intima-media thickness and plaque
Yang, C., Sun, Z., Li, Y., Ai, J., Sun, Q., & Tian, Y. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-181 · Cited by 71
TAVINTHARAN, S., Ong, C. N., Jeyaseelan, K., Sivakumar, M., Lim, S. K., & Sum, C. F. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.05.013 · Cited by 71
Macphee, C. H., NELSON, J., & Zalewski, A. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.008 · Cited by 71
Murrow, J. R., Sher, S., Ali, S., Uphoff, I., Patel, R. S., Porkert, M., Le, N., Jones, D. P., & Quyyumi, A. A. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.006 · Cited by 71
Farnier, M., Averna, M. R., Missault, L. H., Vaverková, H., Viigimaa, M., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., & Brudi, P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02022.x · Cited by 71
Castro, P., Miranda, R., Verdejo, H., Greig, D. P., Gabrielli, L., Alcaíno, H., Chiong, M., Bustos, C., Garcı́a, L., Mellado, R., et al. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.012 · Cited by 71
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 71
Arca, M., Veronesi, C., D’Erasmo, L., Borghi, C., Colivicchi, F., Ferrari, G. M. D., Desideri, G., Pontremoli, R., Temporelli, P. L., Perrone, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015801 · Cited by 71
HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size
Yamakuchi, M., Greer, J. J. M., Cameron, S. J., Matsushita, K., Morrell, C. N., Fox-Talbot, K., Baldwin, W. M., Lefer, D. J., & Lowenstein, C. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170229.49776.81 · Cited by 71
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
